Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S. provides expert guidance and practical know-how for lawyers working in this burgeoning area of the law. This is your opportunity to meet the authors who contributed to this comprehensive guide and go-to reference for all things biosimilars.
Q&A with March’s Featured Author: Alexandra Valenti
Alexandra Valenti is a partner in the firm’s New York office.
What made you want to contribute to the Guide?
As regular BMW readers know, we have been closely following the legal landscape for biosimilars for many years. Although the blog provides a great resource for of-the-minute news, I was excited about the opportunity to put all of that information in one place as a topically organized, go-to resource for our clients and others in the industry.
What do you hope people learn from the Guide?
That this is a dynamic field in which parties are pursuing creative arguments on very important issues, and that such creativity has so far had a real impact on biosimilar launch timing.
What did you learn from working on the Guide?
My colleagues are incredibly knowledgeable, thoughtful, and passionate about these issues, and I’m lucky to work with them. (Okay, I already knew that!)
Feel free to contact the authors should you have questions or wish to discuss any topics covered in the Guide or on Big Molecule Watch.
Alexandra Valenti: avalenti@goodwinlaw.com